Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come

Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2013-05, Vol.57 (5), p.1691-1693
Hauptverfasser: Ghonem, Nisanne S., Boyer, James L.
Format: Artikel
Sprache:eng
Schlagworte:
Anticholesteremic Agents - therapeutic use
Bezafibrate - therapeutic use
Cholagogues and Choleretics - therapeutic use
Female
Humans
Liver Cirrhosis, Biliary - drug therapy
Liver diseases
Male
Ursodeoxycholic Acid - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1693
container_issue 5
container_start_page 1691
container_title Hepatology (Baltimore, Md.)
container_volume 57
creator Ghonem, Nisanne S.
Boyer, James L.
description
doi_str_mv 10.1002/hep.26155
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4048949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3050320441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5095-a6990bc41eea326411c10ddcf436502d248f402921843b772a78a08c2463e13f3</originalsourceid><addsrcrecordid>eNp1kV1L5DAUhoOs6Phx4R-Qwt7oRfXkq228WJDBXQVBL_Q6ZNJTm6FtxqSdZf79Zh1XdheEwAmchyfn5CXkhMIFBWCXLa4uWEGl3CEzKlmZcy7hC5kBKyFXlKt9chDjEgCUYNUe2WeclkIpPiPP390imBFjZtKpl9PaDGM2thjMapM1PmS2DX5wNlXfYRzNmO6dW2PIahfRRLzK7saYja7HrE0S63s8IruN6SIev9fD9M7N0_w2v3_4cTe_vs-tBCVzUygFCysoouGsEJRaCnVtG8ELCaxmomoEMMVoJfiiLJkpKwOVZaLgSHnDD8m3rXc1LXqsLQ5jMJ1eBdebsNHeOP1vZ3CtfvFrLUBUSqgkOHsXBP86pfV076LFrjMD-ilqyoWU6QMVJPTrf-jST2FI62kqWCGFqhRL1PmWssHHGLD5GIaC_h2WTmHpt7ASe_r39B_kn3QScLkFfroON5-b9O3N41b5C01JnYQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1426549892</pqid></control><display><type>article</type><title>Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ghonem, Nisanne S. ; Boyer, James L.</creator><creatorcontrib>Ghonem, Nisanne S. ; Boyer, James L.</creatorcontrib><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.26155</identifier><identifier>PMID: 23174993</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Anticholesteremic Agents - therapeutic use ; Bezafibrate - therapeutic use ; Cholagogues and Choleretics - therapeutic use ; Female ; Humans ; Liver Cirrhosis, Biliary - drug therapy ; Liver diseases ; Male ; Ursodeoxycholic Acid - therapeutic use</subject><ispartof>Hepatology (Baltimore, Md.), 2013-05, Vol.57 (5), p.1691-1693</ispartof><rights>Copyright © 2012 American Association for the Study of Liver Diseases</rights><rights>Copyright © 2012 by the American Association for the Study of Liver Diseases. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5095-a6990bc41eea326411c10ddcf436502d248f402921843b772a78a08c2463e13f3</citedby><cites>FETCH-LOGICAL-c5095-a6990bc41eea326411c10ddcf436502d248f402921843b772a78a08c2463e13f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.26155$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.26155$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23174993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghonem, Nisanne S.</creatorcontrib><creatorcontrib>Boyer, James L.</creatorcontrib><title>Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Bezafibrate - therapeutic use</subject><subject>Cholagogues and Choleretics - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Cirrhosis, Biliary - drug therapy</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Ursodeoxycholic Acid - therapeutic use</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1L5DAUhoOs6Phx4R-Qwt7oRfXkq228WJDBXQVBL_Q6ZNJTm6FtxqSdZf79Zh1XdheEwAmchyfn5CXkhMIFBWCXLa4uWEGl3CEzKlmZcy7hC5kBKyFXlKt9chDjEgCUYNUe2WeclkIpPiPP390imBFjZtKpl9PaDGM2thjMapM1PmS2DX5wNlXfYRzNmO6dW2PIahfRRLzK7saYja7HrE0S63s8IruN6SIev9fD9M7N0_w2v3_4cTe_vs-tBCVzUygFCysoouGsEJRaCnVtG8ELCaxmomoEMMVoJfiiLJkpKwOVZaLgSHnDD8m3rXc1LXqsLQ5jMJ1eBdebsNHeOP1vZ3CtfvFrLUBUSqgkOHsXBP86pfV076LFrjMD-ilqyoWU6QMVJPTrf-jST2FI62kqWCGFqhRL1PmWssHHGLD5GIaC_h2WTmHpt7ASe_r39B_kn3QScLkFfroON5-b9O3N41b5C01JnYQ</recordid><startdate>201305</startdate><enddate>201305</enddate><creator>Ghonem, Nisanne S.</creator><creator>Boyer, James L.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201305</creationdate><title>Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come</title><author>Ghonem, Nisanne S. ; Boyer, James L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5095-a6990bc41eea326411c10ddcf436502d248f402921843b772a78a08c2463e13f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Bezafibrate - therapeutic use</topic><topic>Cholagogues and Choleretics - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Cirrhosis, Biliary - drug therapy</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Ursodeoxycholic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghonem, Nisanne S.</creatorcontrib><creatorcontrib>Boyer, James L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghonem, Nisanne S.</au><au>Boyer, James L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2013-05</date><risdate>2013</risdate><volume>57</volume><issue>5</issue><spage>1691</spage><epage>1693</epage><pages>1691-1693</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>23174993</pmid><doi>10.1002/hep.26155</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2013-05, Vol.57 (5), p.1691-1693
issn 0270-9139
1527-3350
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4048949
source MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals
subjects Anticholesteremic Agents - therapeutic use
Bezafibrate - therapeutic use
Cholagogues and Choleretics - therapeutic use
Female
Humans
Liver Cirrhosis, Biliary - drug therapy
Liver diseases
Male
Ursodeoxycholic Acid - therapeutic use
title Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T20%3A12%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibrates%20as%20adjuvant%20therapy%20for%20chronic%20cholestatic%20liver%20disease:%20Its%20time%20has%20come&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Ghonem,%20Nisanne%20S.&rft.date=2013-05&rft.volume=57&rft.issue=5&rft.spage=1691&rft.epage=1693&rft.pages=1691-1693&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.26155&rft_dat=%3Cproquest_pubme%3E3050320441%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1426549892&rft_id=info:pmid/23174993&rfr_iscdi=true